

Research Priorities for Preventing and Treating Alzheimer's Disease and Related Dementias

Committee

Patricia (Tia) Powell

Chair

Tia Powell, MD (Chair), holds the Shoshanah Trachtenberg Frackman Chair in Medical Ethics, and is Professor of Epidemiology and Psychiatry at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Powell focuses on bioethics issues related to public policy, aging, dementia, end-of-life care, and public health disasters. She served 4 years as Executive Director of the New York State Task Force on Life and the Law, which was New York State's bioethics commission. Dr. Powell has worked with NASEM on many projects, and in 2021 chaired the report Committee for Reducing the Impact of Dementia in America: a Decadal Survey of Behavioral and Social Sciences. She has worked with the CDC, NY State and City, and various professional organizations on issues related to public health ethics and disasters. She served as a special advisor to AHRQ on ethics, dementia and multiple chronic conditions. She is on the American Psychiatric Association ethics committee, is a Fellow of NYAM and the Hastings Center, and has previously served as a subject matter expert at advisory board meetings. She wrote *Dementia Reimagined: Building a Life of Joy and Dignity from Beginning to End*, published in 2019 by Penguin Random House. Dr. Powell received a BA from Harvard College and MD from Yale Medical School.

Rhoda Au

Member

Rhoda Au, PhD, MBA, is a Professor of Anatomy & Neurobiology, Neurology, Medicine, and Epidemiology at Boston University Chobanian & Avedisian School of Medicine. She serves as one of the principal investigators of the Framingham Heart Study Brain Aging Program and is the Director of Neuropsychology. She also serves as the Director of Global Cohort Development for the Davos Alzheimer's Collaborative. Her research and work include the application of technologies to promote equal opportunity in science and to develop and validate multi-sensor digital biomarkers. Her long-term research objective is to enable global solutions that move the primary focus of health technologies from precision medicine to a broader emphasis on precision brain health. She graduated with her Ph.D. in Cognitive Psychology from the University of California, Riverside in 1985 and her MBA from Boston University in 1995. In addition to these research activities, she currently advises several pharmaceutical and biotechnology companies on the development of digital biomarkers for use in clinical research in the development of novel AD/ADRD therapeutics. These include Signant Health, Biogen, and Novo Nordisk. She has previously attended advisory board meetings of a companies involved in AD/ADRD research, including Kaiser Permanente, Eisai, TauRx, Merck, Novartis, and Roche, and has served as a reviewer of grants for the Alzheimer's Drug Discovery Foundation and the Alzheimer's Association. She currently serves as an advisor to a several NIH-funded studies, including the Alzheimer's Disease Neuroimaging Initiative and Adult Changes in Thought study, and as a standing member for the Neurological, Mental and Behavioral Health study section of the National Institute on Aging. Dr. Au currently sits on the editorial review board of the Journal of Alzheimer's Disease. She was recently selected to receive the 2023 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery from the Alzheimer's Disease Drug Discovery Foundation.

Rita J. Balice-Gordon

Member

Rita Balice-Gordon, PhD, is Chief Executive Officer of Muna Therapeutics, a preclinical biotech company focused on disease modifying therapies for neurodegenerative diseases. She is also a Director on the Board of Collegium Pharmaceutical, a publicly traded company; a Director on the Board of Capsida BioTherapeutics, a biotech company innovating new genomic medicines; and a consultant for Praesidia Therapeutics, a pharmaceutical company developing drugs for cancers and central nervous system disorders. Prior to taking on these roles, Dr. Balice-Gordon was the Global Head of the Rare and Neurologic Diseases Therapeutic Area at Sanofi, Inc. where she led work on research and early development stage projects for patients with neurodegenerative diseases including multiple sclerosis, Parkinson's, and amyotrophic lateral sclerosis, and rare genetic disorders including lysosomal storage diseases, inborn errors of metabolism, and renal and musculoskeletal diseases. Prior to Sanofi, she held senior leadership roles in the Neuroscience and Pain Research Unit at Pfizer. Prior to her career in biopharma, Dr. Balice-Gordon was Professor of Neuroscience and Chair of the Neuroscience Graduate Group in the Perelman School of Medicine at the University of Pennsylvania, where she holds an appointment as Adjunct Professor. She was continuously funded by the NIH for more than 30 years, authored more than 100 scientific papers, received several awards and honors, has given hundreds of invited talks around the world, and has chaired or served on many NIH, national and international committees, study sections, editorial boards, and research organization advisory boards. She is currently a member of the Neuroscience Forum of the National Academies of Sciences, Engineering, and Medicine. Dr. Balice-Gordon is an elected Fellow of the American Association for the Advancement of Science.

Daniel S. Barron

Member

Daniel S. Barron, MD, PhD, directs the Pain Intervention and Digital Research Program at Mass General Brigham, where he is funded by the National Institute of Aging (K01) to define digital markers of functional status in older patients with chronic pain conditions. His lab is also funded by the Brain and Behavior Research Foundation (NARSAD). He is an interventional pain physician and psychiatrist who specializes in the treatment of chronic musculoskeletal pain—specifically neck and back pain—and offers the latest evidence-based treatments that include pharmacologic, interventional, and rehabilitative therapy.

Christian Behl

Member

Christian Behl, PhD, is Director of the Institute of Pathobiochemistry at the University Medical Center of the Johannes Gutenberg University Mainz, Germany, where he is Full Professor and Chair since 2002. Dr. Behl holds a Diploma in Biology from the University of Würzburg, Germany, where he also received his PhD in Neurobiology 1991. Following his postdoc research on Alzheimer's Disease from 1992 to 1994 at the Salk Institute for Biological Studies, La Jolla, USA, he headed an Independent Research Group on aging and neurodegeneration at the Max-Planck-Institute for Psychiatry in Munich from 1994-2002. In Mainz, Dr. Behl has translated his long-standing interest in neurodegenerative diseases into a research focus on autophagy, proteostasis, and oxidative stress in the context of age-related neurodegeneration. One of his key research goals is to uncover molecular mechanisms that allow neurons to resist challenges occurring during neurodegenerative diseases. For the past decade, Dr. Behl has been closely following research on widening the view on Alzheimer's disease in order to improve the understanding of this complex, age-related brain disorder. He has received several awards including the AGNP Award for Psychopharmacology Research, and the Binder Innovation Prize of the German Society for Cell Biology. He is a member of the Board of the German Alzheimer Foundation.

Jeffrey L. Dage

Member

Jeffrey Dage, PhD, is a Senior Research Professor of Neurology at Indiana University School of Medicine and a primary member of the Stark Neurosciences Research Institute. He received his Ph.D. from the University of Cincinnati in Ohio where he worked in the area of protein characterization using mass spectrometry. He previously worked in the pharmaceutical industry for 28 years and has contributed to many therapeutic discovery programs through analytical measurement of biologically relevant molecules in cell culture, preclinical models, and human clinical samples. At Eli Lilly, he led the discovery and development of the first biofluid tests to measure P-tau181 and P-tau217, which could reliably predict the presence of Alzheimer's neuropathologic change and shifted the global landscape of Alzheimer's disease clinical research. He is continuing his research at Indiana University, focusing on the implementation of blood tests in clinical research as well as the discovery and development of novel biomarkers for Alzheimer's disease and related dementias. Dr. Dage provides advisory services to ALZPath, Inc., Genotix Biotechnologies, Inc., and Prevail Therapeutics and is a co-founder of and consultant for Monument Biosciences, all of which are involved in the development of novel treatments for AD/ADRD. He has previously consulted for AbbVie and Eisai. Dr. Dage is a co-inventor of two patents relating to a fluid biomarker for diagnosing Alzheimer's disease and frontotemporal dementia and the prevention of neuronal axonal damage in Alzheimer's disease. Dr. Dage also serves as Vice Chair of the Biofluid Based Biomarkers Professional Interest Area for the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment and on the Scientific Program Committee of the Alzheimer's Association.

Nilufer Ertekin-Taner

Member

Nilüfer Ertekin-Taner, MD, PhD, is Chair of the Department of Neuroscience, a Professor of Neurology and Neuroscience at Mayo Clinic. She is a physician-scientist with seminal contributions to the field of Alzheimer's disease and related neurodegenerative conditions. Her innovative, groundbreaking work combining complex genomics and deep endophenotypes is essential for the discovery of molecular disease mechanisms, new treatments and biomarkers for these devastating and currently incurable conditions. She has pioneered the endophenotype approach in genetic studies of Alzheimer's Disease and related disorders. Her laboratory applies leading-edge analytic approaches to integrate biological traits with multi-omics data to discover precision medicine therapies and biomarkers in ADRD. Ertekin-Taner is a PI of AMP-AD and Resilience-AD and was a PI of M2OVE-AD consortia and Florida Consortium for African American AD Studies (FCA3DS). She is the contact PI of the CLEAR-AD U19 Program comprising 13 sites and nearly 100 investigators focused on precision medicine biomarker and therapeutic discoveries in ADRD. Dr. Ertekin-Taner has been continually funded by the National Institutes of Health and foundations, having served or serving as a Principal Investigator (PI) on 37 grants with total extramural grant support of about \$80 million since 2008. Her lab is a leader in many national large-scale initiatives aiming to discover precision medicine therapies in Alzheimer's and related disorders. Owing to her prolific, impactful work, Dr. Ertekin-Taner serves on numerous executive committees and advisory boards including the NIH-funded Framingham Heart Study Executive Committee and the TREAT-AD Consortium External Advisory Board. Ertekin-Taner is the recipient of numerous awards including the 2022 Alzheimer's Association Zenith Fellows Award. She also serves as a board-certified neurologist, she continues to care for dementia patients. Dr. Ertekin-Taner is also a leader in education serving as Director and PI for Mayo Clinic Center for Clinical and Translational Science (CCaTS) KL2 Mentored Career Development Program, as Founding Chair of the Mayo Clinic Research Pipeline K2R Program and as a mentor to over 80 trainees to date from various career stages.

Maria Glymour

Member

Maria Glymour, ScD, is a professor and chair of the Department of Epidemiology at Boston University's School of Public Health and serves on the leadership group of the Methods in Longitudinal Research on Dementia initiative. Her research focuses on how social factors experienced across the life course, from infancy to adulthood, influence cognitive function, dementia, stroke, and other health outcomes in old age. She is especially interested in education and other exposures amenable to policy interventions. She has also worked on the influence of "place" on health, for example to understand the excess stroke burden for individuals who grew up in the US Stroke Belt and evaluating effects of immigration. She works with a network of colleagues on the international initiative MELODEM (Methods for Longitudinal Studies in Dementia) to foster adoption of rigorous causal inference methods and evidence triangulation approaches to understand how to eliminate social inequalities in dementia risk and improve dementia related outcomes. She currently serves on a National Institute on Aging advisory board for longitudinal dementia research. Dr. Glymour received her ScD in Social Epidemiology from Harvard School of Public Health and her AB in Biology from the University of Chicago.

Hector M. Gonzalez

Member

Hector M. González, PhD, is a Professor of Neurosciences at the UC San Diego School of Medicine. He is a population neuroscientist who previously held faculty posts in departments of epidemiology and public health in Michigan. His primary professional expertise is in cognitive assessment of aging and diverse Hispanics/Latinos. Dr. González' primary research expertise is in examining modifiable health and sociocultural factors related to healthy cognitive aging, and unhealthy cognitive aging, impairment, and disorders among diverse Hispanics/Latinos at the population level. Dr. González is PI of the NIH/NIA-funded Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) and leads a research program based on the lifecourse research framework for cognitive aging and Alzheimer's disease among diverse US Latinos to leverage this deeply phenotyped and genotyped representative cohort. He has served as a panelist and chair of three Alzheimer's Disease and Related Dementia Summits (2016, 2019, 2022) and serves on the advisory boards of several NIA-funded Alzheimer's Disease Research Centers and studies. Dr. González' education and training are in clinical neuropsychology and epidemiology. Beginning over 20 years ago as a fellow, Dr. González assessed Mexican-American patients in clinics and oversaw cognitive assessments of 1,789 older Mexican-American participants of the Sacramento Area Latino Study of Aging (SALSA). Dr. González served the NRC as a panelist for the 2021 Behavioral and Social Research and Clinical Practice Implications of Biomarker and other Preclinical Diagnostics of Alzheimer's Disease (AD) and AD Related Dementias (AD/ADRD). In addition, he was a workshop panelist on the 2023 Addressing Structural Constraints Preventing Transformative Change and Highlighting Community-Driven Collaborations.

Susanne M. Jaeggi

Member

Susanne M. Jaeggi, PhD, is Professor at Northeastern University, where she's affiliated with the Center for Cognitive and Brain Health, and the Departments of Psychology, Applied Psychology, and Music. She co-directs the Brain Game Center for Mental Fitness and Well Being. Previously, she was Professor in Education and Cognitive Science at the University of California, Irvine, where she directed the Working Memory and Plasticity Lab. She received PhDs in Cognitive Psychology and Neuroscience, as well as a 'Habilitation' from the University of Bern in Switzerland, and she conducted postdoctoral work in Cognitive Neuroscience at the University of Michigan. Her research program focuses on understanding individual differences in executive functions and related cognitive domains, as well as their malleability across the lifespan using experimental and neuroscientific approaches. Because of the relevance of those cognitive domains in educational settings and daily life, her major work has focused on the development of assessments and interventions, and whether and how executive functions can be improved with both, experience and targeted training. Furthermore, she is particularly interested in understanding the underlying mechanisms of learning and cognitive training, and determining for what individuals and populations cognitive training is most effective and why. Her work has been funded by NIH (NIA, NIMH), NSF, ONR, or the Advanced Education Research and Development Fund (AERDF; EF+Math Program).

Kenneth Langa

Member

Kenneth Langa, MD, PhD, is the Cyrus Sturgis Professor in the Department of Internal Medicine and Institute for Social Research at the University of Michigan. He is also Co-Principal Investigator of the Health and Retirement Study (HRS), and Principal Investigator of the Harmonized Cognitive Assessment Protocol (HCAP) Project, both funded by the National Institute on Aging. Dr. Langa's research focuses on the epidemiology and costs of chronic disease in older adults, with an emphasis on Alzheimer's disease and related dementias, and he has published more than 325 peer-reviewed articles on these topics. Dr. Langa received an MD and PhD in Public Policy at the University of Chicago as a Fellow in the Pew Program for Medicine, Arts, and the Social Sciences. He is a General Internist with 29 years of clinical experience treating adult patients, an elected member of the American Society for Clinical Investigation (ASCI), and an elected fellow of the American Association for the Advancement of Science (AAAS). Dr. Langa was a member of the 2017 NAM Committee on Preventing Dementia and Cognitive Impairment.

Pamela J. Lein

Member

Pamela J. Lein, PhD, MS, is currently Professor of Neurotoxicology and Chair of the Department of Molecular Biosciences at the UC Davis School of Veterinary Medicine with a faculty appointment in the UC Davis MIND Institute. She previously was on the faculty at Oregon Health and Science University and the Johns Hopkins University Bloomberg School of Public Health. Her research focuses on the cellular and molecular mechanisms by which environmental stressors, including toxic chemicals, contribute to neurodevelopmental and neurodegenerative disorders. Dr. Lein was selected as an AAAS fellow in 2023, and received the 2023 AAVMC Excellence in Research Award, 2022 Distinguished Neurotoxicologist Award from the Society of Toxicology (SOT), and the 2022 Mentoring Award from the SOT Women in Toxicology Special Interest Group. Dr. Lein has held numerous leadership positions in SOT and is a member of the AAAS. Dr. Lein earned a BS Degree in Biology with honors from Cornell University, MS in Environmental Health from East Tennessee State University, and PhD in Pharmacology and Toxicology from the University of Buffalo. She did postdoctoral training in Molecular Immunology at Roswell Park Cancer Institute. She has served on several NASEM committees focused on toxicological concerns and currently serves on the NASEM Committee on Toxicology. She serves as Chair of the Working Group of the National Advisory Neurological Disorders and Stroke (NANDS) Council on the Neural Exposome and as Chair of the Board of Scientific Counselors for the NIEHS National Toxicology Program.

Rita Doreen Monks

Member

Rita Doreen Monks, MSN, BSN, RN, is a retired Neuroscience Nurse Practitioner. She retired after a 41-year Nursing career. Prior to her retirement, she was the Program Director of the Stroke Program at Saint Barnabas Medical Center, Livingston, New Jersey. This was a program that she personally developed. She now volunteers as an Advocate and Community Educator for the Greater NJ Chapter of the Alzheimer's Association as well as a community educator and dementia advocate for several other venues. Ms. Monks is living with early-stage Alzheimer's Disease and shares her experiences with the disease with interested stakeholders, this has previously included a pharmaceutical company, for which she received a small honorarium. Doreen advances scientific understanding of Alzheimer's disease as a participant in a randomized clinical trial for an investigational treatment for Alzheimer's Disease. She recently received the Governor's Award for Volunteerism from Governor Murphy of NJ. She holds her RN diploma from Clara Maass School of Nursing, her BSN from the Regents External Degree Program, and a Master's Degree from Seton Hall University.

Krissan M. Lutz Moss

Member

Krissan Lutz Moss, RN, BSN, is a retired Clinical Education Manager and Thought Leader Liaison. She previously worked for Genentech, USA and now volunteers with the National Council of Dementia Minds, which creates opportunities for dialogue and education for persons living with dementia, licensed health care professionals, researchers, families, care partners, policymakers, and communities at large about strategies for how to live well with Neurocognitive Disorders.

Kenneth S. Ramos

Member

Kenneth S. Ramos, MD, PhD, is a Professor of Translational Medical Sciences, Alkek Chair of Medical Genetics, Director of the Center for Genomic and Precision Medicine, Associate Vice President for Research, and Assistant Vice Chancellor for Health Services for the Texas A&M University System. He is an accomplished physician-scientist with designations in the National Academy of Medicine (elected member) and National Academy of Sciences (lifetime associate). He is a transformational leader recognized throughout the world for his scientific contributions in the areas of genomics, precision medicine, and toxicology. He leads several initiatives to elucidate genetic and molecular mechanisms of disease, improve healthcare, and reduce disease burden and health-associated costs. He is also involved in studies to evaluate functional genetic networks of human retrotransposons and their clinical utility as prognostic and diagnostic biomarkers of cancer, point-of-care precision medicine approaches with a focus on pharmacogenomics in primary and specialty care practice, magnetic resonance-based and integrative interventions to promote brain health.

Reisa A. Sperling

Member

Reisa A. Sperling, MD, MMSc, is a neurologist focused on the detection and treatment of Alzheimer's disease at the earliest possible stage. Dr. Sperling is a Professor in Neurology at Harvard Medical School, Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, and Director of Neuroimaging for the Massachusetts Aging & Disability Resource Consortia at Massachusetts General Hospital. In addition to these roles, she serves on the leadership team for the NIH-funded Alzheimer's Clinical Trials Consortium (NIH competitive award U24AG057437) and as principal investigator of several global, multi-center randomized trials of regimens to prevent cognitive decline in individuals at high risk for developing Alzheimer's disease and in those with pre-clinical disease. Two of these ACTC studies for which she is PI involve public-private partnership clinical trials with Eisai and Eli Lilly. Separately from her work with the ACTC, she also applies her expertise in consultation with pharmaceutical and biotechnology companies on their clinical trial design and testing of candidates in their pipelines, including AbbVie, AC Immune, Alector, Acumen, Bristol Myers Squibb, Genentech, Janssen, Neuraly, Oligomerix, Prothena, Renew, Vaxxinity, Merck, and Biohaven. She has previously provided consulting services to several other companies involved in Alzheimer's disease research, including Alnylam, Cytos, JMDD, Nervgen, Neurocentria, Shionogi, Virgil Neuroscience, Ionis, and Biogen. She has served on multiple NIH, national and international committees related to advancing the study of AD/ADRD treatment and prevention. Dr. Sperling chaired the 2011 NIA-Alzheimer's Association workgroup to develop guidelines for the study of "Preclinical Alzheimer's disease" and serves as a member of the current Alzheimer's Association Workgroup on Revised Criteria for Diagnosis and Staging of Alzheimer's Disease. She co-led the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) and LEARN Studies, and currently co-leads the AHEAD 3-45 Studies. Dr. Sperling received the 2015 Potamkin Prize from the American Academy of Neurology, a Lifetime Achievement Award from Clinical Trials in Alzheimer's Disease in 2022 and was elected to the National Academy of Medicine in 2021.

Chinedu T. Udeh-Momoh

Member

Chi Udeh-Momoh, PhD, MSc, BSc, is a Translational Neuroscientist with expertise in dementia epidemiology, based across Aga Khan University Kenya and Wake Forest University, USA; and affiliated as a Senior Scientist with Karolinska Institute. In her dual roles as Director of the Imarisha Centre for Brain Health and Aging and Lead of the Genomics and Biomarker Core at the Brain and Mind Institute Kenya, she is developing capacity for dementia and brain aging research, education, and care while collaborating with Mental Health and Neuroscience subject experts, clinicians, and educators across the Aga Khan University, to ultimately build the neuroscience capacity and strength across Global South regional partner institutions, including Pakistan. At Wake Forest University, she leads the Udeh-Momoh Lab for Global Brain Health Equity (U-M = BRAIN) focusing on translational research to advance equitable and culturally-informed strategies for promoting successful aging. She is also an Atlantic Fellow for Equity in Brain Health. In 2018, she initiated the AFRICA-FINGERS project (as Chief Investigator) that aims to promote healthy aging and mitigate brain health and biomarker-access inequalities through culturally appropriate, sustainable multimodal intervention strategies in African populations. She is also co-founder of the Female Brain and Endocrine Research (FEMBER) consortium. Having completed a competitive CASE PhD studentship in Neuroscience and Neuroendocrinology at the MRC. Centre for Synaptic Plasticity at the University of Bristol (2010-2014), her research elucidates dementia prevention bio-mechanistic pathways and strategies across diverse populations, adopting a translational approach integrating human clinical studies with experimental animal models. She previously worked at Imperial College London, where components of her research received funding from industry. She currently receives competitively awarded funding for her research efforts from Wellcome Leap, the Alzheimer's Association, the Davos Alzheimer's Collaborative, and the Global Brain Health Institute. Dr. Udeh-Momoh leads multinational initiatives to address gender and racial disparities in medical research and academia and sits on the Board of Trustees of the British Society for Neuroendocrinology as the Equity, Diversity and Inclusion Lead.

Li-San Wang

Member

Li -San Wang, PhD, is the Peter C. Nowell Professor and Vice Chair for Research, Department of Pathology and Laboratory Medicine and Founding Co-Director of the Penn Neurodegeneration Genomics Center (PNGC) at the University of Pennsylvania Perelman School of Medicine. Dr. Wang's lab focuses on the genetics and genomics of Alzheimer's disease and other neurodegenerative disorders, and informatics and algorithm development for genome-scale experiments. He is PI of National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) and MPI of the Genome Center for Alzheimer's Disease (GCAD), both strategic initiatives to coordinate Alzheimer's genetics research, including Alzheimer's Disease Sequencing Project (ADSP) that will analyze genomic sequences of Alzheimer's patients and cognitively normal age-matched individuals to find novel genetic variants linked to the disease. He is founding PI of the Asian cohort for Alzheimer's disease (ACAD), the first major international study on genetics of dementia in Asian Americans and Asian Canadians. He is a member of the external advisory board for the Framingham Heart Study Brain Aging Program and the Adult Changes in Thought study, which are funded by the National Institute on Aging. Dr. Wang is a senior member of the International Society of Computational Biology. He received BS and MS in Electrical Engineering from National Taiwan University, and PhD in Computer Sciences from the University of Texas at Austin. He then received his Postdoctoral Training at the University of Pennsylvania for three years before his began faculty appointment.

Julie M. Zissimopoulos

Member

Julie Zissimopoulos, PhD, is a Professor at the Sol Price School of Public Policy at the University of Southern California. She is a Senior Fellow at USC's Schaeffer Center for Health Policy and Economics where she leads a research program on aging and cognition. Additionally, she serves as the Principal Investigator (mPI organization) and Director of two NIA-funded centers: The Center for Advancing Sociodemographic and Economic Study of Alzheimer's Disease and Related Dementias (CeASES-ADRD) and the USC Alzheimer's Disease and Related Dementias Resource Center for Minority Aging Research (USC AD/ADRD RCMAR). Dr. Zissimopoulos' research focuses on caregiving and healthcare costs associated with dementia, health disparities in dementia risk, diagnosis and detection, and medical care for individuals living with dementia. Her work also encompasses medication adherence and insurance design. Dr. Zissimopoulos actively contributes to the research community by serving as the Health Policy Editor for Alzheimer's and Dementia, Journal of the Alzheimer's Association. She is an advisory board member for the NIA-funded Center for Aging and Policy Studies at Syracuse University and the Center on Aging and Population Sciences at University of Texas, Austin. She also serves as an Independent Study Monitoring officer for the University of Minnesota project, Refining a Driving Cessation Management Intervention for Person with Dementia and their Family Caregivers: CarFreeMe. Dr. Zissimopoulos served as co-Chair of the National Institute on Aging, 2023 National Research Summit on Care, Services, and Supports for Persons Living with Dementia and Their Care Partners/Caregivers. She also served on the Committee on the Decadal Survey of Behavioral and Social Science Research on Alzheimer's Disease and Alzheimer's Disease Related Dementias for the National Academy of Sciences. She received her PhD in Economics from the University of California, Los Angeles.